PriceTargets.com logo

Fractyl Health - GUTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 967.96%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.06 As of 11/20/2024 01:00 AM ET
▼ -0.13 (-5.94%)

This chart shows the closing price for GUTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fractyl Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GUTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GUTS

Analyst Price Target is $22.00
▲ +967.96% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Fractyl Health in the last 3 months. The average price target is $22.00, with a high forecast of $26.00 and a low forecast of $18.00. The average price target represents a 967.96% upside from the last price of $2.06.

This chart shows the closing price for GUTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Fractyl Health.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/28/2024Evercore ISIInitiated CoverageOutperform
2/27/2024Morgan StanleyInitiated CoverageOverweight$18.00
2/27/2024Bank of AmericaInitiated CoverageBuy$26.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 4 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2024
  • 5 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
10/21/2024
  • 2 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 2 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fractyl Health logo
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $2.06
Low: $2.02
High: $2.24

50 Day Range

MA: $2.50
Low: $1.97
High: $3.40

52 Week Range

Now: $2.06
Low: $1.74
High: $14.50

Volume

294,472 shs

Average Volume

480,253 shs

Market Capitalization

$99.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Fractyl Health?

The following equities research analysts have issued research reports on Fractyl Health in the last year: Bank of America Co., Evercore ISI, and Morgan Stanley.
View the latest analyst ratings for GUTS.

What is the current price target for Fractyl Health?

0 Wall Street analysts have set twelve-month price targets for Fractyl Health in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 968.0%. Bank of America Co. has the highest price target set, predicting GUTS will reach $26.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $18.00 for Fractyl Health in the next year.
View the latest price targets for GUTS.

What is the current consensus analyst rating for Fractyl Health?

Fractyl Health currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GUTS will outperform the market and that investors should add to their positions of Fractyl Health.
View the latest ratings for GUTS.

What other companies compete with Fractyl Health?

Other companies that are similar to Fractyl Health include Tactile Systems Technology, ZimVie, AVITA Medical, Nano-X Imaging and CVRx. Learn More about companies similar to Fractyl Health.

How do I contact Fractyl Health's investor relations team?

Fractyl Health's physical mailing address is 17 Hartwell Avenue, Lexington, MA 02421, United States. The company's listed phone number is 781-902-8800 and its investor relations email address is [email protected]. The official website for Fractyl Health is fractyl.com. Learn More about contacing Fractyl Health investor relations.